All filters
Abstracts
Open-Label, Drug-Drug Interaction Study between HIV-1 Maturation Inhibitor (MI) GSK3640254 and Tenofovir Alafenamide (TAF)/Emtricitabine (FTC) in Healthy Participants
T. Pene Dumitrescu
Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Pharmacokinetics, Safety, and Tolerability of Single- and Multiple Ascending Doses of Jnj-64417184, a Non-Nucleoside Inhibitor of Respiratory Syncytial Virus Polymerase, in Healthy Volunteers
M. Pastagia
Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Abstracts
Single-Ascending Dose (SAD) Pharmacokinetics of Hepatitis B Virus (HBV)-Specific JNJ-73763989 in Non-Japanese and Japanese Healthy Volunteers (HV)
T. Kakuda
Reviews in Antiviral Therapy & Infectious Diseases 4, 2020
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2020
Videos
Leveraging Reverse Transcriptase 2020 | Judith Currier
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Anton Pozniak
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Laura Waters
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Jean-Michel Molina
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Chloe Orkin
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Martin Markowitz
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase 2020 | Daniel Kuritzkes
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Videos
Leveraging Reverse Transcriptase in HIV | Judith Currier
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase | Pozniak
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Waters
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Molina
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Orkin
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Markowitz
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Kuritzkes
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Slidesets
Leveraging Reverse Transcriptase 2020 | Currier
Presented at:
Leveraging Reverse Transcriptase in HIV: Past, Present, and Future 2020
Abstracts
Protein binding determination of second-line anti-tuberculosis drugs in vitro using an ultrafiltration technique
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Comparison of a Bayesian forecasting algorithm handling inter-occasion variability and a linear regression approach for dose individualization of rifampicin
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Mathematical modeling using in vitro checkerboard assay data: Clofazimine as a potentially synergistic anti-TB drug
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Levofloxacin urine kinetics and development of a colorimetric assay for therapeutic drug monitoring among people living with HIV and TB
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019
Abstracts
Optimal dose individualisation of rifampicin needs to account for between-occasion variability
Presented at:
International Workshop on Clinical Pharmacology on HIV, Hepatitis and Other Antiviral Drugs 2019